[ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "N2XsExtuSmDqhsNyTCiQWOKqjpX7taazpFSQ99SWIAbaHj6jaicozOpU3De70jiapB2C44dxRltVljWre2CYuHWaTpJy4ddi2C3GPWJy8Dn4dVS+VwujvHRTEyfs1GiqCakDLzkAig6jOYw7NmIEeQTi6+2lX5kGTB7lWV/c4Bo=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M" } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-25T19:56:26.456+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-7641-6446" } ], "http://purl.org/nanopub/x/supersedes": [ { "@id": "http://purl.org/np/RABKQoWBPe2xHiJO1OWK6-thNeldFTB3JfKDn0FT2dBSY" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" }, { "@id": "http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAZdZj78B6nKrP1Q00oFzsK07u7WdiY3sToz-H-H2nSgg" } ] } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#Head", "@graph": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#provenance", "@graph": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-7641-6446" } ] } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/MONDO_0002046", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/MONDO_0002046" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://go.drugbank.com/drugs/DB00181" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." } ], "https://w3id.org/biolink/vocab/association_type": [ { "@id": "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/has_population_context": [ { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#cohort" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/publications": [ { "@id": "https://pubmed.ncbi.nlm.nih.gov/28658981/" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://w3id.org/um/neurodkg/OffLabelIndication" } ] }, { "@id": "https://go.drugbank.com/drugs/DB00181", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] }, { "@id": "http://purl.org/np/RAZRqDsdRCWHa35VzOwFxRPb2e6pk_OTbJKSdw5Pnwa8M#cohort", "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "Adults" } ], "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Cohort" } ] } ] } ]